Back to Journals » OncoTargets and Therapy » Volume 10

Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report

Authors Ma FC, Yu Q, Zeng ZM, He RQ, Mo CH, Zhong JC, Ma J, Feng ZB, Chen G, Hu XH

Received 13 July 2017

Accepted for publication 30 September 2017

Published 1 November 2017 Volume 2017:10 Pages 5237—5242

DOI https://doi.org/10.2147/OTT.S146051

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Fu-Chao Ma,1 Qian Yu,1 Zhi-Ming Zeng,1 Rong-Quan He,1 Chao-Hua Mo,2 Jin-Cai Zhong,1 Jie Ma,1 Zhen-Bo Feng,2 Gang Chen,2 Xiao-Hua Hu1

1Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, 2Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

Abstract: Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase inhibitor that targets the intracellular domain of vascular endothelial growth factor receptor-2. To the best of our knowledge, this is the first case report of the successful use of apatinib for advanced ICC; this treatment has demonstrated fewer toxic effects than traditional cytotoxic chemotherapy. The progression-free survival time was 8 months. The only toxicity observed was mild hand–foot syndrome. Therefore, apatinib may be an additional option for the treatment of advanced ICC, but further prospective studies are needed to optimize the treatment.

Keywords: advanced intrahepatic cholangiocarcinoma, apatinib, PFS, cholangiocarcinoma, VEGFR-2, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study

Gao L, Li SH, Tian YX, Zhu QQ, Chen G, Pang YY, Hu XH

OncoTargets and Therapy 2017, 10:3667-3683

Published Date: 20 July 2017